Lupin gets USFDA approval of sNDA for SOLOSEC (secnidazole) to treat trichomoniasis EP News Bureau Jul 1, 2021 SOLOSEC demonstrated a 92.2 per cent clinically and statistically significant cure rate for patients with trichomoniasis based on…
Lupin presents Phase 3 data for Solosec in female patients with trichomoniasis EP News Bureau Aug 14, 2020 The company plans to submit a supplemental New Drug Application for Solosec to the FDA for the treatment of trichomoniasis later…
